Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...
LOS ANGELES, March 27 (Reuters) - An angina drug made by CV Therapeutics Inc. failed to prove effective as a treatment for acute coronary syndrome, but favorable safety data could broaden its use, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results